iBio, Inc. (NYSE MKT: IBIO) is a clinical-stage biotechnology company that utilizes proprietary plant-based expression systems to accelerate the development and manufacture of biotherapeutics. The company’s FastPharming platform enables rapid production of vaccines, monoclonal antibodies and other complex proteins in plant hosts, providing a cost-effective and scalable alternative to traditional mammalian cell culture processes.
iBio’s pipeline includes vaccine candidates for emerging infectious diseases such as Zika, influenza and coronaviruses, as well as antibody programs targeting oncology and autoimmune disorders. Through research collaborations and partnerships with government agencies and academic institutions, the company advances programs designed to meet global public health needs while exploring applications of its plant-derived proteins in industrial and consumer markets.
Founded in 2006 and headquartered in College Station, Texas, iBio has established a network of research and manufacturing collaborations across North America, Europe and Asia. The company’s origins in pioneering academic work on plant expression have evolved into a fully integrated bioprocessing platform, with multiple candidates having progressed through preclinical stages toward clinical development.
iBio is guided by a leadership team with extensive experience in biologics development, process engineering and regulatory affairs. Under the direction of President and Chief Executive Officer Jim Levine, the company’s management and board of directors are committed to commercializing its proprietary manufacturing technologies and advancing a robust pipeline of high-value biotherapeutics.
AI Generated. May Contain Errors.
Free IBIO Stock Alerts